ライフサイエンスコーパス: disease-free survival

1 ch are clinically relevant and forecast poor disease-free survival.

2 th a non-inferiority margin of 3% for 4-year disease-free survival.

3 ng p62 and FERMT2 as adverse determinants of disease-free survival.

4 to the standard 12-month treatment regarding disease-free survival.

5 eic transplant leads to acceptable long-term disease-free survival.

6 node yield from esophagectomy on overall and disease-free survival.

7 rimary end point was noninferior (6% margin) disease-free survival.

8 ilable for 3903 patients for the analyses of disease-free survival.

9 and that this response would correlate with disease-free survival.

10 n KCNQ1:KCNE3 channel complex expression and disease-free survival.

11 toxicity, overall survival (OS), and distant disease-free survival.

12 ed both progression-free survival and 1-year disease-free survival.

13 ar results were observed for both groups for disease-free survival.

14 sulting in high rates of ocular survival and disease-free survival.

15 The secondary outcome was disease-free survival.

16 cholesterolemia, is associated with improved disease-free survival.

17 levels have a detrimental impact on patient disease-free survival.

18 rimidines, although the effect was mainly on disease-free survival.

19 Primary outcome was 3-year disease-free survival.

20 of pooled analysis were overall survival and disease-free survival.

21 ositive tumor cells correlate with shortened disease-free survival.

22 d PVRL1 was associated with shorter times of disease-free survival.

23 nt were associated with recurrence and lower disease-free survival.

24 e and lymphovascular invasion and with lower disease-free survival.

25 d in TCGA with higher grade tumors and worse disease-free survival.

26 d histopathologic factors and recurrence and disease-free survival.

27 re also associated with recurrence and lower disease-free survival.

28 fficacy end points were similar to those for disease-free survival.

29 on <15% were independent predictors of lower disease-free survival.

30 points were 5-year locoregional control and disease-free-survival.

31 percentage of local recurrence or decreased disease-free-survival.

32 zole treatment did not significantly improve disease-free survival (339 disease-free survival events

33 rval 1.38-6.34; P = 0.005) and a decrease of disease-free survival (53.6% vs 70.9%; hazard ratio 1.67

34 Differences in disease-free survival according to BCLC and Child-Pugh c

35 apy was significantly associated with poorer disease-free survival (adjHR, 1.83; 95% CI, 1.15 to 2.92

36 hether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibit

37 Proportion of patients who achieved pCR and disease-free survival after neoadjuvant treatment accord

38 itor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant t

39 significantly improved the rates of invasive-disease-free survival among patients with HER2-positive,

40 The primary endpoint was disease-free survival analysed by intention to treat wit

41 The primary endpoint was disease-free survival, analysed by intention to treat, w

42 endpoint of the 5-year analysis was invasive disease-free survival, analysed by intention to treat.

43 The primary endpoint was disease-free survival, analysed by the intention-to-trea

44 ith clinical endpoints reflecting overall or disease-free survival and a pathologic complete response

45 ectomy was shown to be associated with worse disease-free survival and higher recurrence rates than w

46 anscript levels were associated with shorter disease-free survival and higher tumor grade.

47 remetastatic lung produces longer periods of disease-free survival and increased overall survival, co

48 dpoints in the COLOR and COLOR II trial were disease-free survival and local recurrence at 3-year fol

49 apy was associated with significantly better disease-free survival and locoregional failure-free inte

50 rable AML according to European LeukemiaNet, disease-free survival and OS were significantly improved

51 and PB-MRD response ( P = .024 and .027 for disease-free survival and OS, respectively).

52 Times of disease-free survival and overall survival did not diffe

53 trials with completed accrual and available disease-free survival and overall survival results for t

54 association between hazard ratios (HRs) for disease-free survival and overall survival using R(2).

55 We measured the association between disease-free survival and overall survival using Spearma

56 t-level and trial-level correlations between disease-free survival and overall survival.

57 Primary outcomes were disease-free survival and overall survival.

58 sed to evaluate the association of PMRT with disease-free survival and overall survival.

59 tize RAMS11 due to its association with poor disease-free survival and promotion of aggressive phenot

60 OS from 89% to 93% at 4 years, with improved disease-free survival and reduction in the rate of dista

61 Secondary end points included disease-free survival and the cumulative rate of nonsent

62 The primary endpoint was disease-free survival and the trial aimed to detect 5% d

63 Ocular survival, disease-free survival and time to regression of seeds we

64 Primary endpoint is disease-free survival, and analyses are in the intention

65 For MALT lymphomas, local control, disease-free survival, and overall survival are good wit

66 nce-free rate, distant metastasis-free rate, disease-free survival, and overall survival in the patie

67 nts were complete pathologic response (pCR), disease-free survival, and overall survival rates.

68 iation with respect to 5-year local control, disease-free survival, and overall survival.

69 ching on lymph node ratio, adjuvant therapy, disease-free survival, and recurrence site, additional t

70 nal, trial-based endpoints such as survival, disease-free survival, and safety, calls for a new frame

71 Ocular survival, disease-free survival, and time to regression of seeds.

72 breast tumors, factors associated with lower disease-free survival are non-nodular enhancement, size>

73 rt, HER2DX was significantly associated with disease-free survival as a continuous variable (HR 2.77,

74 st that it is appropriate to continue to use disease-free survival as a surrogate for overall surviva

75 Disease-free survival at 1, 2, and 3 years were 53%, 44%

76 The primary endpoint was disease-free survival at 10 years of follow-up.

77 Disease-free survival at 10 years was 67% (95% CI 65-69)

78 roscopic hysterectomy resulted in equivalent disease-free survival at 4.5 years and no difference in

79 The primary endpoint of the LACC trial was disease-free survival at 4.5 years, and quality of life

80 uppressive regimens have been used with poor disease-free survival at long-term follow-up.

81 ought to determine whether there is improved disease-free survival benefit to taking the active drug

82 ional (TEAM) trial reported no difference in disease-free survival between exemestane monotherapy and

83 ial aimed to detect 5% differences in 5-year disease-free survival between the treatment groups.

84 ee time-to-event end points were considered: disease-free-survival, breast cancer-free interval, and

85 The primary end point was disease-free survival by intention to treat.

86 To evaluate conditional disease-free survival (CDFS) for patients who underwent

87 score of 2 or less had a much better 5-year disease-free survival compared to those having a score o

88 se of intermittent letrozole did not improve disease-free survival compared with continuous use of le

89 rozole therapy did not significantly prolong disease-free survival compared with placebo.

90 east cancer significantly improves long-term disease-free survival, compared with observation.

91 survival (iDFS; primary end point), distant disease-free survival (D-DFS), and overall survival (OS)

92 ed 5-year event-free survival (EFS), distant disease-free survival (DDFS), overall survival (OS), and

93 o examine its effects on short-term, distant disease-free survival (DDFS).

94 Disease Free Survival decreased significantly if macrosc

95 Disease Free Survival decreased significantly if macrosc

96 The primary endpoint was disease-free survival, defined as time from randomisatio

97 Disease-free survival, defined as time from randomizatio

98 the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, resp

99 , we aimed to develop a new model to predict disease free survival (DFS) after surgical removal of pr

100 The primary outcomes were disease free survival (DFS) and overall survival (OS).

101 I patients tended to be associated with poor disease free survival (DFS) in univariate analysis (p =

102 strong prognostic indicator (p = 0.0006) of disease free survival (DFS) on our OSCC test cohort.

103 iii) local and distant recurrence (LR), (iv) disease free survival (DFS), (v) overall survival (OS).

104 by accounting for the changing likelihood of disease-free survival (DFS) according to time elapsed af

105 n the 2 groups for overall survival (OS) and disease-free survival (DFS) according to whether or not

106 The primary end point was disease-free survival (DFS) after a median of 5 years of

107 Landmark analyses at maintenance compared disease-free survival (DFS) among those receiving all pr

108 Disease-free survival (DFS) and metastasis-free survival

109 Survival analysis uncovered the worse disease-free survival (DFS) and overall survival (OS) as

110 ety and efficacy of adjuvant girentuximab on disease-free survival (DFS) and overall survival (OS) in

111 Markers were tested for prognostic value for disease-free survival (DFS) and overall survival (OS) us

112 Primary and secondary end points were disease-free survival (DFS) and overall survival (OS), e

113 omes include local control, distant control, disease-free survival (DFS) and overall survival (OS).

114 II colon cancer and the prognostic effect on disease-free survival (DFS) and overall survival (OS).

115 cancer on locoregional recurrence (LRR) and disease-free survival (DFS) at 2 years.

116 The primary objective was to compare disease-free survival (DFS) between both arms.

117 Primary end points were pregnancy rate, and disease-free survival (DFS) between patients with and wi

118 abine would improve the postinduction 5-year disease-free survival (DFS) compared with intrathecal me

119 external results, was investigator-reported disease-free survival (DFS) comparing 3 years of sorafen

120 rimary end point of the study was to improve disease-free survival (DFS) from 14 to 18 months by addi

121 The 4-year disease-free survival (DFS) from end-induction was 85.9%

122 termined from the initiation of neoadjuvant, disease-free survival (DFS) from the date of surgery, an

123 to demonstrate a primary end point of 2-year disease-free survival (DFS) greater than 85%, improving

124 a meta-analysis of overall survival (OS) and disease-free survival (DFS) in 6042 patients from four c

125 tion and postoperative capecitabine improves disease-free survival (DFS) in locally advanced rectal c

126 Median disease-free survival (DFS) in the entire cohort was 21.

127 and Trastuzumab trial demonstrated a 3-year disease-free survival (DFS) of 98.7%.

128 The disease-free survival (DFS) of patients with MDM2rs22797

129 Two-year overall (OS) and disease-free survival (DFS) of the whole series was 56%

130 The mean disease-free survival (DFS) rate was 24.1 +/- 2.5 months

131 The 5-year disease-free survival (DFS) rates for patients with T-AL

132 al volume and both overall survival (OS) and disease-free survival (DFS) using data obtained from the

133 Disease-free survival (DFS) was the primary endpoint, an

134 Five-year overall survival (OS) and disease-free survival (DFS) was worse for all categories

135 urvival (OS), event-free survival (EFS), and disease-free survival (DFS) were 78.2%, 58.1%, and 72.3%

136 Cancer-specific survival (CSS) and disease-free survival (DFS) were calculated by log-rank

137 Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-

138 Overall survival (OS) and disease-free survival (DFS) were evaluated among a 52-we

139 Although the primary endpoint of improved disease-free survival (DFS) with sirolimus was not met,

140 e-specific survival (DSS), imaging-confirmed disease-free survival (DFS), and local progression-free

141 The secondary endpoints were toxicity, disease-free survival (DFS), and overall survival at 1 y

142 econdary endpoints were 3-year overall (OS), disease-free survival (DFS), and recurrence rates.

143 The primary end point was 5-year disease-free survival (DFS), and the key secondary end p

144 ependently predict overall survival (OS) and disease-free survival (DFS), in patients who underwent r

145 ed alterations (trunk-ratio) had a prolonged disease-free survival (DFS), regardless of the influence

146 is associated with overall survival (OS) and disease-free survival (DFS), respectively.

147 Primary endpoint was disease-free survival (DFS), secondary endpoints were ov

148 nt adjuvant sunitinib trial showing improved disease-free survival (DFS), the appropriate strategy fo

149 to determine the prognostic impact of TD on disease-free survival (DFS).

150 ereas the remaining 60% experience long-term disease-free survival (DFS).

151 nd surgery predicted a shorter postoperative disease-free survival (DFS); Charlson comorbidity index

152 The primary end point was disease-free survival (DFS); secondary end points were o

153 (2 of 28 patients) and overall had a longer disease-free survival (DFS; 190.1 vs. 100.2 months; P <

154 ine as postremission therapy with respect to disease-free survival (DFS; primary end point) and overa

155 the instantaneous hazard of recurrence (ie, disease-free survival [DFS]) stratified by anti-HER2 Th1

156 rence, 3- or 5-year overall survival(OS) and disease free survival(DFS) between the two approaches.

157 Disease-free survival did not differ significantly betwe

158 Secondary end points included overall and disease-free survival, disease recurrence, and organ pre

159 rates of infections, mucositis, relapse, and disease-free survival during induction and postinduction

160 Ocular survival, disease-free survival, ERG: peak-to-peak ERG amplitudes

161 7-year disease-free survival estimate was 81.3% (95% CI 79.3-83

162 stuzumab significantly reduced the risk of a disease-free survival event (HR 0.76, 95% CI 0.68-0.86)

163 7) for both treatment groups, during which a disease-free survival event occurred in 265 (13%) of 204

164 d a 9% relative reduction in the hazard of a disease-free survival event with letrozole (hazard ratio

165 3045 patients in the sequential group had a disease-free survival event.

166 median follow-up 10 years [IQR 10-10]), 1087 disease-free survival events and 914 deaths had occurred

167 tinib group had significantly fewer invasive disease-free survival events than those in the placebo g

168 s were reported in the placebo group and 292 disease-free survival events were reported in the letroz

169 ificantly improve disease-free survival (339 disease-free survival events were reported in the placeb

170 cluding 18 endometrial cancer deaths, and 80 disease-free survival events.

171 ghly predictive of treatment outcome; 5-year disease-free survival for MRD-negative patients (n = 125

172 One year probabilities of overall and disease-free survival for the entire cohort, including p

173 phosphamide, and rituximab (FCR) can improve disease-free survival for younger (age <=65 years) fit p

174 ohorts of up to 301 cases into good and poor disease-free survival groups (14VF HR = 2.4, 14GT HR = 3

175 cally significantly associated with improved disease-free survival (> 14 v <= 8 MET-hours/week/year;

176 hough frequently used as a primary endpoint, disease-free survival has not been validated as a surrog

177 utcome on adjuvant chemotherapy for invasive disease-free survival (hazard ratio (HR) = 0.42; 95% con

178 on was independently associated with shorter disease-free survival (Hazard Ratio (HR) for relapse 3.5

179 Adjuvant chemotherapy significantly improved disease-free survival (hazard ratio 0.45, 95% CI 0.30-0.

180 lage was an independent predictor of shorter disease-free survival (hazard ratio 1.99, 95% CI 1.07-3.

181 15) that significantly associated with worse disease-free survival (hazard ratio 2.23, 95% CI 1.58 to

182 ng endocrine therapy was related to improved disease-free-survival (hazard ratio [HR], 0.79; 95% CI,

183 4; HR 1.2, 95% CI 1.2-1.3, respectively) and disease-free survival (HR 1.3, 95% CI 1.2-1.3; HR 1.2, 9

184 4; HR 1.2, 95% CI 1.2-1.3, respectively] and disease-free survival (HR 1.3, 95% CI 1.2-1.3; HR 1.2, 9

185 onic acid was associated with lower invasive-disease-free survival (HR 2.47, 95% CI 1.23-4.97) and ov

186 er were significantly associated with better disease-free survival (HR = 0.46, 95% CI 0.36-0.61, p =

187 nvasive margin were associated with improved disease-free survival (HR = 0.57, 95% CI 0.38-0.86, p =

188 ) was strongly associated with both improved disease-free survival (HR, 0.33; 95% CI, 0.17 to 0.64; P

189 from pre- to postdiagnosis also had improved disease-free survival (HR, 0.35; 95% CI, 0.18 to 0.69) a

190 00; 95% CI, 0.78 to 1.28; P = 1.00), distant disease-free survival (HR, 1.12; 95% CI, 0.86 to 1.47; P

191 lity (NRM) (HR, 1.50; P < .01), and inferior disease-free survival (HR, 1.41; P = .02).

192 etic stem cell transplantation had increased disease-free survival (HR, 7.2; 95% CI: 1.6-33; p = 0.01

193 th a statistically significant difference in disease-free survival (HR: 0.93; 95% CI: 0.48, 1.79) or

194 vival: HR, 0.37; 95% CI, 0.15-0.93; invasive disease-free survival: HR, 0.58; 95% CI, 0.34-1.01; all

195 he TaxAC regimens was planned, with invasive disease-free survival (IDFS) as the primary end point.

196 hs (range, 0.5 to 64.0 months), 243 invasive disease-free survival (iDFS) events were reported (143 i

197 s stratified by trial were used for invasive disease-free survival (iDFS; primary end point), distant

198 its high expression correlates with adverse disease free survival in clinical samples.

199 Intestinal deletion of Bcl9 extends disease-free survival in both models, and essentially cu

200 confers no therapeutic advantage in terms of disease-free survival in early breast cancer, although i

201 al replication stress in vitro and long-term disease-free survival in mice with B-ALL, without detect

202 er nephroureterectomy significantly improved disease-free survival in patients with locally advanced

203 y stage colorectal cancer, especially longer disease-free survival in patients with microsatellite in

204 brafish thyroid cancer that is predictive of disease-free survival in patients with papillary thyroid

205 oped for predicting the probability of early disease-free survival in patients with resected pancreat

206 associated with better overall survival and disease-free survival in the combination of both cohorts

207 , MAF status was not prognostic for invasive-disease-free survival in the control group (MAF-positive

208 5-year disease-free survival in the HER2DX low-risk group was 9

209 The primary outcome was disease-free survival in the intention-to-treat populati

210 operator identified features that predicted disease-free survival in the training cohort.

211 pression significantly associated with worse disease-free survival in two cohorts of localized PCa.

212 significantly improves overall survival and disease-free survival in women with HER2-positive early

213 e versus chemoendocrine therapy for invasive disease-free survival in women with Oncotype DX scores p

214 of 9 vascular features (9VF) that predicted disease-free-survival in a discovery cohort (n = 64, HR

215 Since recurrence rates are higher and disease-free survival is lower for minimally invasive ra

216 e the impact of leakage on overall survival, disease-free survival, local and distant recurrences, ad

217 TK inhibitors, and in most cases, long-term disease-free survival may only be achievable with alloge

218 285 patients (56.1%) recurred after a median disease-free survival (mDFS) of 17.2 months.

219 mbra, and bone marrow identifies lung cancer disease-free survival more accurately than clinical feat

220 vaccine, thereby accounting for the improved disease-free survival observed with combination therapy.

221 thological classification and post-treatment disease-free survival of patients with adenocarcinoma of

222 or, tumor penumbra, and bone marrow predicts disease-free survival of patients with non-small cell lu

223 c-Jun mRNA level was associated with shorter disease-free survival of patients with TNBC.

224 varied across the trials analysed: two used disease-free survival, one used progression-free surviva

225 nd RS were univariate prognostic factors for disease-free survival; only nodal status, both central a

226 breast cancer-specific survival and invasive disease-free survival (OS: HR, 0.45; 95% CI, 0.21-0.96;

227 CHER-LOB, Hospital Clinic, and Padova) with disease-free survival outcome data.

228 ears of adjuvant trastuzumab did not improve disease free-survival outcomes compared with 1 year of t

229 Few randomized trials have compared disease-free survival outcomes for surgical approaches.

230 phagectomy, without compromising overall and disease-free survival over a period of 3 years.

231 ctor for poor overall, disease-specific, and disease-free survival (p <= 0.011).

232 cumulative incidence of relapse (P = .028), disease-free survival (P = .03), and event-free survival

233 that overall survival (P=1.91 x 10(-5)) and disease-free survival (P=4.9 x 10(-5)) was poorer for TC

234 f APLNR in NPC predicted a better prognosis (disease-free survival: P = 0.001; overall survival: P <

235 The disease-free survival rate difference was 0.3% (favoring

236 Tissue microarray analysis showed that the disease-free survival rate for patients with high-expres

237 The 24-month disease-free survival rate from time of CR was 90.9% in

238 We assumed a 3-year invasive-disease-free survival rate of 91.8% with pertuzumab and

239 Six-year disease-free survival rate was 55% for AS + RT and 65% f

240 The 2-year invasive disease-free survival rate was 93.9% (95% CI 92.4-95.2)

241 g mediators (SPM) called resolvins increases disease-free survival rates and prevents metastasis afte

242 ) macrophages that were associated with 5-yr disease-free survival rates of 27.8% and 0.2%, respectiv

243 ontrol rates to be 93.1%; 5-year and 10-year disease-free survival rates to be 75.7% and 71.0%, respe

244 Five-year disease-free survival rates were 39% in the FU plus LV a

245 of initial resection, ITT 5-year overall and disease-free survival rates were 69% and 60%, respective

246 homas (884 patients), the 5-year and 10-year disease-free survival rates were reported to be 86.4% an

247 The overall survival and disease-free survival rates were significantly worse for

248 BRCA1 and BRCA2 alterations showed elevated disease-free survival rates when carboplatin was added (

249 mised phase 3 trials was done to investigate disease-free survival regarding non-inferiority of 3 mon

250 e detected in steroid-refractory acute GVHD, disease-free survival, relapse, nonrelapse mortality, or

251 Updated disease-free survival results confirmed previous finding

252 patients and that these patients have lower disease-free survival than patients without elevated SNH

253 at the time of diagnosis resulted in longer disease-free survival than score 3 to 4 (P = 0.044).

254 nic acid was associated with higher invasive-disease-free survival than was control treatment (HR 0.7

255 rrogate threshold effect, the maximum HR for disease-free survival that statistically predicts an HR

256 The primary endpoint was disease-free survival; the secondary endpoint, invasive-

257 lymphoma (HL) treatment have led to improved disease-free survival, this has been accompanied by an i

258 In the 10 studies describing disease-free survival, this was significantly improved i

259 er diversity) were not associated with worse disease-free survival, though the HR for >=Q3 was 2.32 (

260 The primary endpoint was disease-free survival (time to relapse, secondary colore

261 nce-free, liver-tumor-free, and extrahepatic disease-free survival was >=86%, >=50%, >=57%, and >=65%

262 In arms A and B, respectively, 5-year disease-free survival was 31.2% and 16.2%, event-free su

263 % CI, 45 to 64) in the open-procedure group; disease-free survival was 57% (95% CI, 47 to 66) and 48%

264 In the intention-to-treat population, 5-year disease-free survival was 77.6% (95% CI 70.6-83.2) with

265 The 10-year disease-free survival was 80.2% in the SLND alone group

266 At 4.5 years of follow-up, disease-free survival was 81.3% in the TAH group and 81.

267 months (95% CI, 48 to 60 months) the 5-year disease-free survival was 82% (95% CI, 77% to 89%), and

268 The 5-year BCF disease-free survival was 85% in both arms (hazard ratio

269 a median follow-up of 60 months (IQR 53-72), disease-free survival was 85.8% (95% CI 84.2-87.2) in th

270 p of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was

271 4-year disease-free survival was 89.4% (95% CI 87.9-90.7) in th

272 The 5-year invasive disease-free survival was 90.2% (95% CI 88.3-91.8) in th

273 ositive disease, the 3-year rate of invasive-disease-free survival was 92.0% in the pertuzumab group,

274 a median follow-up of 4.1 years, the 5-year disease-free survival was 92.2% (95% CI, 88.6 to 95.8) a

275 egative disease, the 3-year rate of invasive-disease-free survival was 97.5% in the pertuzumab group

276 magnitude of trastuzumab benefit on distant disease-free survival was higher for increasing expressi

277 Disease-free survival was higher in patients with the CC

278 tant recurrence was 14.6% LAP and 16.7% OPEN.Disease-free survival was impacted by unsuccessful resec

279 l was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had a

280 5% [62-67] in the control group), and median disease-free survival was not reached (adjusted hazard r

281 Disease-free survival was not reported for these 2 studi

282 No association with relapse or disease-free survival was observed.

283 two-sided statistical significance level for disease-free survival was set at 0.0418.

284 Invasive disease-free survival was significantly higher in the T-

285 The rate of disease-free survival was slightly higher in the dissect

286 e survival; the secondary endpoint, invasive-disease-free survival, was the primary disease endpoint

287 ar cumulative incidence of relapse (CIR) and disease-free survival were 36% and 60% for gHiR patients

288 The 2-year probabilities of overall and disease-free survival were 51% and 43%, respectively.

289 Estimates of 10-year disease-free survival were 63% for observation, 69% for

290 he estimates of the 3-year rates of invasive-disease-free survival were 94.1% in the pertuzumab group

291 aplan-Meier estimates of ocular survival and disease-free survival were 94.2% (95% confidence interva

292 ns between physical activity and overall and disease-free survival were assessed using Cox proportion

293 Ocular survival and disease-free survival were estimated using Kaplan-Meier

294 igh lymph node yield on overall survival and disease-free survival were included.

295 The 18-month Kaplan-Meier estimates of disease-free survival were significantly worse for the O

296 Median overall and disease-free survivals were significantly better in the

297 her in the tumors of patients with long-term disease-free survival when compared to patients that rel

298 The primary outcome was disease-free survival, which was measured as the interva

299 KATHERINE (NCT01772472), have shown improved disease-free survival with postoperative capecitabine an

300 erse events and no significant difference in disease-free survival with the 3-month regimen.